To assess improvement in renal impairment when switching from imatinib mesylate to second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia
Latest Information Update: 17 Apr 2017
Price :
$35 *
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics
- 17 Apr 2017 New trial record